Security record · archived quarter
AKRO
Akero Therapeutics, Inc. · Healthcare · Biotechnology
8Tracked holders
n/aΔ holders
11.90MShares held
$279.29MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 5.11M | n/a | $119.99M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 2 | T. Rowe Price ✦ | 4.15M | n/a | $97.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 1.62M | n/a | $37.99M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 395.12K | n/a | $9.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 315.72K | n/a | $7.41M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 169.59K | n/a | $3.98M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 120.07K | n/a | $2.82M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 24.10K | n/a | $565,386 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API